ClinicalTrials.gg
TerminatedNCT05099822Updated Dec 14, 2023

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

A Phase 1 interventional study of CC-97489 and Placebo in Healthy Volunteers, sponsored by Celgene. Terminated at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business objectives changed.

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Mar 2020, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study aims to evaluate the safety, tolerability, of CC-97489

02

Conditions studied

  • Healthy Volunteers

Keywords

  • CC-97489
  • Healthy Adult
  • Phase1
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good health, as determined by the investigator based on past medical history, physical examination, vital signs and clinical laboratory safety tests at screening.
  • (BMI) ≥ 18 and ≤ 33 kg/m\^2, inclusive. BMI = weight (kg)/(height [m])\^2

Exclusion criteria

Exclusion Criteria:

  • Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, echocardiogram (), or clinical laboratory determinations beyond what is consistent with healthy participants

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Administration of CC-97489

    Drug: CC-97489

  • Experimental
    Administration of Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986368

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: 28 days after the last dose

  2. Incidence of Serious Adverse Events (SAEs)

    Time frame: 28 days after the last dose

  3. Number of participants with clinically significant changes in electrocardiogram parameters

    Time frame: Day 21

  4. Incidence of clinically significant changes in vital signs: Body temperature

    Time frame: Day 21

  5. Incidence of clinically significant changes in vital signs: Respiratory rate

    Time frame: Day 21

  6. Incidence of clinically significant changes in vital signs: Blood pressure

    Time frame: Day 21

  7. Incidence of clinically significant changes in vital signs: Heart rate

    Time frame: Day 21

  8. Incidence of clinically significant changes in clinical laboratory results: Hematology tests

    Time frame: Day 18

  9. Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests

    Time frame: Day 18

  10. Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

    Time frame: Day 18

Secondary outcomes

  1. Pharmacokinetics - Maximum observed plasma concentration (Cmax)

    Time frame: Up to 96 hours after the last dose of study drug

  2. Pharmacokinetics - Minimum plasma drug concentration (Cmin)

    Time frame: Up to 96 hours after the last dose of study drug

  3. Pharmacokinetics - Time to maximum observed plasma concentration (Tmax)

    Time frame: Up to 96 hours after the last dose of study drug

  4. Pharmacokinetics - Area under the plasma concentration (AUC)-time curve from time zero extrapolated to infinity (AUC0-∞)

    Time frame: Up to 96 hours after the last dose of study drug

  5. Pharmacokinetics - Area under the plasma concentration-time curve from time zero to time t, where t is the time point of the last measurable concentration (AUC0-t)

    Time frame: Up to 96 hours after the last dose of study drug

  6. Pharmacokinetics - Area under the plasma concentration-time curve from time zero to 24 hours postdose (AUC0-24)

    Time frame: Up to 96 hours after the last dose of study drug

  7. Pharmacokinetics - Area under the plasma concentration-time curve from time zero to tau (τ) where τ is the dosing interval (AUC0- 0-τ)

    Time frame: Up to 96 hours after the last dose of study drug

  8. Pharmacokinetics - Terminal elimination half-life in plasma (t½,z)

    Time frame: Up to 96 hours after the last dose of study drug

  9. Pharmacokinetics - Apparent total plasma clearance when dosed orally (CL/F)

    Time frame: Up to 96 hours after the last dose of study drug

  10. Pharmacokinetics - Apparent total volume of distribution when dosed orally (Vz/F)

    Time frame: Up to 96 hours after the last dose of study drug

  11. Pharmacokinetics - Ratio of accumulation based on Day 1 and Day 14 AUC0- 0-τ and Cmax, as appropriate (Rac)

    Time frame: Up to 96 hours after the last dose of study drug

  12. Pharmacodynamics - Evaluation of monoacylglycerol lipase (MGLL) enzymatic inhibition by CC-97489 in peripheral blood mononuclear cells (PBMCs)

    Time frame: Up to 168 hours after the last dose of study drug

  13. Pharmacodynamics: Peripheral blood mononuclear cell (PBMC) fatty acid amide hydrolase (FAAH) inhibition

    Time frame: Up to 168 hours after the last dose of study drug

  14. Pharmacodynamics - Measurement of : plasma and whole-blood anandamide (AEA) levels

    Time frame: Up to 168 hours after the last dose of study drug

  15. Pharmacodynamics - Measurement of plasma and whole-blood 2-arachidonoylglycerol (2-AG) levels

    Time frame: Up to 168 hours after the last dose of study drug

07

Study locations

1 site
  • Local Institution - 001
    Leuven, Vlaams Brabant 3000, Belgium
08

References and documents

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.celgene.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Jul 2022, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Oct 29, 2021
StartActual
Mar 13, 2020
Primary completionActual
Jul 11, 2022
CompletionActual
Jul 11, 2022
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05099822
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 29, 2021
Start date
Mar 13, 2020
Primary completion
Jul 11, 2022
Completion
Jul 11, 2022
Last update
Dec 14, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irafamdastat

Start the discussion